A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa [Estudio de fase II de BEZ235 en monoterapia administrado por via oral en pacientes con PEComa maligno irresecable o metastasico]
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2014
At a glance
- Drugs Dactolisib (Primary)
- Indications Perivascular epithelioid cell tumours
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
- 09 Jan 2013 New source identified and integrated: European Clinical Trials Database record.